Its expression defines a clinically challenging form of an aggressive breast cancer, which is non-responsive to the standard ErbB2-targeting immunotherapy with trastuzumab and pertuzumab because it lacks their binding sites. This evidence concerns the gene ERBB2 and breast cancer.